Haima Therapeutics
Haima Therapeutics is a pre-clinical stage biotechnology company developing platelet-inspired technologies for the treatment of blood-related diseases. Their mission is to create bio-inspired therapies to mitigate bleeding in various medical conditions, including traumatic injury, surgery, and thrombocytopenia. Their lead product, SynthoPlate, is a fully-synthetic hemostatic technology designed to act at injury sites and enhance natural clotting mechanisms, aiming to address unmet needs in bleeding management and blood product logistics.
Industries
Nr. of Employees
small (1-50)
Haima Therapeutics
Cleveland, Ohio, United States, North America
Products
IV‑injectable synthetic platelet hemostatic agent
A fully synthetic, nanoparticle-based intravenous hemostatic agent designed to localize to vascular injury sites, promote adhesion and aggregation, and reduce bleeding in trauma, surgery, and thrombocytopenia.
Platelet-Inspired Platform Technology
A synthetic nanoparticle platform technology developed by Haima Therapeutics that mimics natural platelet interactions and bioactive cargo delivery.
IV‑injectable synthetic platelet hemostatic agent
A fully synthetic, nanoparticle-based intravenous hemostatic agent designed to localize to vascular injury sites, promote adhesion and aggregation, and reduce bleeding in trauma, surgery, and thrombocytopenia.
Platelet-Inspired Platform Technology
A synthetic nanoparticle platform technology developed by Haima Therapeutics that mimics natural platelet interactions and bioactive cargo delivery.
Services
CMC planning, scale-up strategy, and transfer of nanoparticle manufacturing to GMP-compliant contract manufacturers.
Development and execution of physicochemical and biochemical assays for nanoparticle quality control and characterization (DLS, HPLC, microscopy, MS).
Formulation development for freeze-dried nanoparticle products, accelerated and real-time stability testing, and rapid reconstitution protocols.
Execution of hemorrhage and trauma studies in small and large animal models to assess hemostatic efficacy, safety, and survival outcomes.
Compatibility and co-administration testing with lyophilized plasma and red blood cell surrogates to develop combined field-deployable resuscitation products.
Management of government-funded research awards and coordination across academic, industry, and government partners.
CMC planning, scale-up strategy, and transfer of nanoparticle manufacturing to GMP-compliant contract manufacturers.
Development and execution of physicochemical and biochemical assays for nanoparticle quality control and characterization (DLS, HPLC, microscopy, MS).
Formulation development for freeze-dried nanoparticle products, accelerated and real-time stability testing, and rapid reconstitution protocols.
Execution of hemorrhage and trauma studies in small and large animal models to assess hemostatic efficacy, safety, and survival outcomes.
Compatibility and co-administration testing with lyophilized plasma and red blood cell surrogates to develop combined field-deployable resuscitation products.
Management of government-funded research awards and coordination across academic, industry, and government partners.
Expertise Areas
- Platelet-inspired hemostatic therapeutics
- Nanoparticle and liposome therapeutics
- Lyophilized formulation development
- Preclinical hemorrhage and trauma models
Key Technologies
- Liposome-templated nanoparticles
- Ligand/peptide functionalization of nanoparticles
- Lyophilization / freeze-drying
- Dynamic light scattering (DLS)